Stay updated on Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.

Latest updates to the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded a glossary toggle and updated page metadata to include Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, and Revision: v3.4.0. Removed Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4.SummaryDifference0.1%

- Check22 days agoChange DetectedThe page shows a minor revision update from v3.3.3 to v3.3.4 with no changes to the clinical study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check51 days agoChange DetectedThe Locations section now includes a new Illinois site. The HHS Vulnerability Disclosure link was removed and the page revision updated to v3.3.3.SummaryDifference0.2%

- Check72 days agoChange DetectedRevision: v3.3.2 has been added and Revision: v3.3.1 has been removed.SummaryDifference0.0%

- Check79 days agoChange DetectedRevision tag updated from v3.2.0 to v3.3.1; no changes to trial details, outcomes, eligibility criteria, or locations.SummaryDifference0.0%

- Check86 days agoChange DetectedThe funding status notice about government operations was removed from the page. This notice previously warned that updates may be delayed due to appropriations.SummaryDifference0.2%

Stay in the know with updates to Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.